Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On March1, 2018, Synergy Pharmaceuticals Inc. (the “Company”) issued a press release announcing financial results for the full year and the three months ended December31, 2017 and other matters described in the press release. A copy of the Company’s press release is furnished as Exhibit99.1 to this Current Report on Form8-K.
The information disclosed under this Item 2.02, including Exhibit99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item 2.02. Financial Statements and Exhibits.
(d) Exhibits.
|
99.1 |
Synergy Pharmaceuticals Inc. Press Release dated March1, 2018. |
SYNERGY PHARMACEUTICALS, INC. ExhibitEX-99.1 2 a18-7403_1ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update – TRULANCE® U.S. net sales were $9.4 million in the fourth quarter,…To view the full exhibit click here
About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.
